Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Rarity of B-Cell Receptor Pathway Mutations in Progression-Free Patients With Chronic Lymphocytic Leukemia (CLL) During First-Line Versus Relapsed/Refractory (R/R) Treatment With Ibrutinib

Adrian Wiestner, MD PhD, Paolo Ghia, MD PhD, John C. Byrd, MD, Inhye E Ahn, MD, Carol Moreno, MD PhD, Susan M. O'Brien, MD, Daniel Jones, MD PhD, Leo W. K. Cheung, PhD, Elizabeth Chong, PhD, Kevin Kwei, PhD, James P. Dean, MD PhD, Danelle F. James, MD MAS, Jennifer A. Woyach, MD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-134386

Published: 2020

Journal Articles

Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials

John N. Allan, MD, Tait Shanafelt, MD, Adrian Wiestner, MD PhD, Carol Moreno, MD PhD, Susan M. O'Brien, MD, Esteban Braggio, PhD, Emily Liu, MS, James P. Dean, MD PhD, Dominic Lai, PharmD, Inhye E. Ahn, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-134431

Published: 2020

Journal Articles

Diverging Clonal Evolution during Sequential Therapy with Chemoimmunotherapy Followed By BTK Inhibitors

Inhye E Ahn, MD, Yun-Ching Chen, PhD, Chingiz Underbayev, MD PhD, Erika M Gaglione, Clare Sun, MD, Susan Soto, Pia Nierman, Mehdi Pirooznia, MD PhD, Adrian Wiestner, MD PhD

Blood (2019) 134 (Supplement_1): 850.

https://doi.org/10.1182/blood-2019-122142

Published: 2019

Journal Articles

Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Christopher Pleyer, MD, Jeffrey Cohen, MD, Susan Soto, Mir Ali, PhD, Inhye E Ahn, MD, Pia Nierman, BSN, MA, RN, Janet Valdez, Jennifer Lotter, PA-C, Jeanine Superata, RN, Xin Tian, Adrian Wiestner, MD PhD, Clare Sun, MD

Blood (2019) 134 (Supplement_1): 3053.

https://doi.org/10.1182/blood-2019-121675

Published: 2019

Journal Articles

Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib Show Expansion of T-Cell Clonotypes Composed of Antitumor Cytotoxic CD8+ T-Cells

Maria Joao Baptista, PhD PharmD, Sivasubramanian Baskar, Keyvan Keyvanfar, Erika M Gaglione, Inhye E Ahn, MD, Adrian Wiestner, MD PhD, Clare Sun, MD

Blood (2019) 134 (Supplement_1): 3030.

https://doi.org/10.1182/blood-2019-127131

Published: 2019

Journal Articles

A CD19/CD3 Bispecific Antibody Induces Superior T Cell Responses Against Chronic Lymphocytic Leukemia When Combined with Ibrutinib

Maissa Mhibik, PhD, Erika M Gaglione, Amy Blackburn, Keyvan Keyvanfar, Clare Sun, MD, Inhye E Ahn, MD, Maria Joao Baptista, Junpeng Qi, PhD, Christoph Rader, PhD, Adrian Wiestner, MD PhD

Blood (2019) 134 (Supplement_1): 2861.

https://doi.org/10.1182/blood-2019-126186

Published: 2019

Journal Articles

Risk-Adapted, Ofatumumab-Based Chemoimmunotherapy and Maintenance in Treatment-Naïve CLL: A Phase II Study

Blood (2019) 134 (Supplement_1): 5474.

https://doi.org/10.1182/blood-2019-126698

Published: 2019

Journal Articles

Whole Exome Sequencing Reveals Multiple Driver Events in Chronic Lymphocytic Leukemia Patients with Acquired Ibrutinib Resistance

Chingiz Underbayev, MD PhD, Inhye E Ahn, MD, Hailey Harris, Lauren T Vaughn, Mehdi Pirooznia, MD PhD, Liqiang Xi, MD, Mark Raffeld, MD, Sarah E. M. Herman, Adrian Wiestner, MD PhD

Blood (2019) 134 (Supplement_1): 1287.

https://doi.org/10.1182/blood-2019-127364

Published: 2019

Journal Articles

Validation of Clinical Prognostic Models and Integration of Genetic Biomarkers of Drug Resistance in CLL Patients Treated with Ibrutinib

Inhye E. Ahn, MD, Xin Tian, Maher Albitar, MD, Sarah E. M. Herman, PhD, Erika M. Cook, Susan Soto, Wanlong Ma, David Ipe, L. Claire Tsao, Mei Cheng, James P. Dean, Adrian Wiestner, MD

Blood (2018) 132 (Supplement 1): 186.

https://doi.org/10.1182/blood-2018-99-110326

Published: 2018

Journal Articles

Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)

Clare C. Sun, MD, Pia Nierman, RN, Inhye E. Ahn, MD, Janet Valdez, Jennifer Lotter, Susan Soto, Sarah E. M. Herman, PhD, Todd Covey, PhD, Ahmed Hamdy, MD, Raquel Izumi, PhD, Dongmei Liu, PhD, Priti Patel, MD, Adrian Wiestner, MD

Blood (2018) 132 (Supplement 1): 4424.

https://doi.org/10.1182/blood-2018-99-110395

Published: 2018

Journal Articles

Ibrutinib Increases the Clonality of TCR Repertoire in Patients with Chronic Lymphocytic Leukemia

Maria Joao Baptista, PhD PharmD, Neil Basumallik, Sarah E. M. Herman, PhD, Erika M. Cook, Inhye E. Ahn, MD, Adrian Wiestner, MD, Clare C. Sun, MD

Blood (2018) 132 (Supplement 1): 238.

https://doi.org/10.1182/blood-2018-99-109847

Published: 2018

Journal Articles

Durable Responses to Single-Agent Ibrutinib in Monoallelic—but Not in Biallelic— TP53 Aberrated Patients with Chronic Lymphocytic Leukemia

Christian Brieghel, Inhye E. Ahn, MD, Sarah E. M. Herman, PhD, Adrian Wiestner, MD, Carsten Utoft Niemann

Blood (2018) 132 (Supplement 1): 3111.

https://doi.org/10.1182/blood-2018-99-114472

Published: 2018

Journal Articles

Partial Reconstitution of Humoral and Cellular Immunity in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib

Christopher Pleyer, MD, Clare C. Sun, MD, Pia Niermann, Xin Tian, Inhye E. Ahn, MD, Janet Valdez, Jennifer Lotter, Raquel Izumi, PhD, Ahmed Hamdy, MD, Adrian Wiestner, MD

Blood (2018) 132 (Supplement 1): 1874.

https://doi.org/10.1182/blood-2018-99-111919

Published: 2018

Journal Articles

Serum B-Cell Maturation Antigen As a Biomarker for Chronic Lymphocytic Leukemia Treated with Ibrutinib

Clare Sun, MD, Camilia Soof, BS, Alankrita Taneja, MD, Sarah E. M. Herman, PhD, Erika Cook, BA, Kyle Udd, BA, Haiming Chen, MD PhD, Eric Sanchez, BA, Xin Tian, PhD, Inhye E. Ahn, MD, James R Berenson, MD, Adrian Wiestner, MD

Blood (2017) 130 (Supplement 1): 4031.

https://doi.org/10.1182/blood.V130.Suppl_1.4031.4031

Published: 2017

Journal Articles

Combination of Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with CLL: A Pilot Phase II Study

Inhye E. Ahn, MD, Susan Soto, Pia Nierman, Xin Tian, PhD, Janet Valdez, Jennifer Lotter, Thomas Fleisher, Sergio Rosenzweig, Shakuntala Rampertaap, Irina Maric, Maryalice Stetler-Stevenson, Constance Yuan, Gerald Marti, Adrian Wiestner, MD

Blood (2017) 130 (Supplement 1): 3020.

https://doi.org/10.1182/blood.V130.Suppl_1.3020.3020

Published: 2017

Journal Articles

Activity of CD19/CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia

Hannah R. Robinson, BA, Junpeng Qi, PhD, Sivasubramanian Baskar, PhD, Erika Cook, BA, Inhye E. Ahn, MD, Sarah E. M. Herman, PhD, Christoph Rader, PhD, Adrian Wiestner, MD

Blood (2017) 130 (Supplement 1): 799.

https://doi.org/10.1182/blood.V130.Suppl_1.799.799

Published: 2017

Journal Articles

Improving Depth of Response with Continued Ibrutinib Therapy in CLL Patients

Inhye E. Ahn, MD, Xin Tian, PhD, Jennifer Lotter, Susan Soto, Janet Valdez, Pia Nierman, Maryalice stetler-Stevenson, Constance Yuan, Irina Maric, Adrian Wiestner, MD

Blood (2017) 130 (Supplement 1): 4302.

https://doi.org/10.1182/blood.V130.Suppl_1.4302.4302

Published: 2017

Journal Articles

Prognostic Models Predictive of Disease Progression in CLL Patients Treated with Ibrutinib

Inhye E Ahn, MD, Xin Tian, Susan Soto, Janet Valdez, Jennifer Lotter, Mohammed Farooqui, Adrian Wiestner, MD PhD

Blood (2016) 128 (22): 187.

https://doi.org/10.1182/blood.V128.22.187.187

Published: 2016

Journal Articles

Early Progression of Disease (< 2 Years) Is a Negative Predictor of Survival in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): An Analysis from the Connect ® CLL Registry

Inhye E Ahn, MD, Charles Michael Farber, MD PhD, Matthew Davids, MD, David L. Grinblatt, MD, Nicole Lamanna, MD, Anthony R. Mato, MDMSCE, Chadi Nabhan, MD MBA, FACP, Pavel Kiselev, PhD, Arlene S. Swern, PhD, E. Dawn Flick, RPh, MPH, ScD, Shriya Bhushan, PharmD, Kristen Sullivan, MBA, CCRA, Jeff Sharman, MD, Christopher R. Flowers, MD

Blood (2016) 128 (22): 3581.

https://doi.org/10.1182/blood.V128.22.3581.3581

Published: 2016

Journal Articles

Hyperhemolytic Transfusion Reactions in Non-Sickle Cell Anemia Patients

Inhye E Ahn, MD, Lawrence Rice, MD

Blood (2012) 120 (21): 1183.

https://doi.org/10.1182/blood.V120.21.1183.1183

Published: 2012

NARROW

Rarity of B-Cell Receptor Pathway Mutations in Progression-Free Patients With Chronic Lymphocytic Leukemia (CLL) During First-Line Versus Relapsed/Refractory (R/R) Treatment With Ibrutinib

Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials

Diverging Clonal Evolution during Sequential Therapy with Chemoimmunotherapy Followed By BTK Inhibitors

Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib Show Expansion of T-Cell Clonotypes Composed of Antitumor Cytotoxic CD8+ T-Cells

A CD19/CD3 Bispecific Antibody Induces Superior T Cell Responses Against Chronic Lymphocytic Leukemia When Combined with Ibrutinib

Risk-Adapted, Ofatumumab-Based Chemoimmunotherapy and Maintenance in Treatment-Naïve CLL: A Phase II Study

Whole Exome Sequencing Reveals Multiple Driver Events in Chronic Lymphocytic Leukemia Patients with Acquired Ibrutinib Resistance

Validation of Clinical Prognostic Models and Integration of Genetic Biomarkers of Drug Resistance in CLL Patients Treated with Ibrutinib

Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)

Ibrutinib Increases the Clonality of TCR Repertoire in Patients with Chronic Lymphocytic Leukemia

Durable Responses to Single-Agent Ibrutinib in Monoallelic—but Not in Biallelic— TP53 Aberrated Patients with Chronic Lymphocytic Leukemia

Partial Reconstitution of Humoral and Cellular Immunity in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib

Serum B-Cell Maturation Antigen As a Biomarker for Chronic Lymphocytic Leukemia Treated with Ibrutinib

Combination of Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with CLL: A Pilot Phase II Study

Activity of CD19/CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia

Improving Depth of Response with Continued Ibrutinib Therapy in CLL Patients

Prognostic Models Predictive of Disease Progression in CLL Patients Treated with Ibrutinib

Early Progression of Disease (< 2 Years) Is a Negative Predictor of Survival in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): An Analysis from the Connect ® CLL Registry

Hyperhemolytic Transfusion Reactions in Non-Sickle Cell Anemia Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only